Cancer Immunotherapy Market Sales Revenue Clinical Trials Pipeline Report

With more than 6 Million deaths worldwide in 2013, cancer has become one of the most pressing health problems faced by almost all the economies of the world. Inspite of the fact that there have been significant improvisation and advancements in surgery, radiation therapy, and chemotherapy over the years, there has hardly been any significant control of this disease by these treatments. There have been many developments in the recent past, in terms of introducing novel methods of treatment of cancer, which are likely to have a great potential. Cancer immunotherapy is one such development in the field of cancer treatment. This treatment option involves manipulating the human body’s immune system in order to target the cancer.

Download Report:

https://www.kuickresearch.com/report-Cancer-Immunotherapy-Market-&-Clinical-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Cancer Immunotherapy Market & Clinical Pipeline Insight" Table of Contents

1. Introduction to Cancer Immunotherapy (Page 6)

2. Mechanism of Cancer Immunotherapy (Page 11)
2.1 Genetic engineering
2.2 Hybridoma Technology
2.3 Humanization of Monoclonal Antibodies
2.4 Overcoming the HAMA Response via Modern Technology

3. Types of Cancer Immunotherapy (Page 14)
3.1 Monoclonal Antibodies
3.2 Checkpoint Inhibitors
3.3 Vaccination
3.4 Non Specific Immunotherapies

4. Why Need for Cancer Immunotherapy (Page 23)

5. Global Cancer Immunotherapy Market Overview (Page 26)

6. Cancer Immunotherapy Market Dynamics (Page 33)
6.1 Favorable Market Drivers
6.2 Key issues to be Discussed
6.3 Future of Cancer Immunotherapy

7. Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country (Page 41)
7.1 Clinical Pipeline Overview
7.2 Clinical Pipeline Insight: Research till Registration
7.3 Marketed Cancer Monoclonal Antibodies

8. Cancer Vaccine Clinical Pipeline by Phase & Country (Page 1088)
8.1 Clinical Pipeline Overview
8.2 Clinical Pipeline Insight: Research till Registration
8.3 Marketed Cancer Vaccines

9. Oncolytic Viruses Clinical Pipeline by Phase & Country (Page 1640)
9.1 Clinical Pipeline Overview
9.2 Clinical Pipeline insight: Research till Registration

10. Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country (Page 1714)
10.1 Clinical Pipeline Overview
10.2 Clinical Pipeline Insight: Research till Preregistration
10.3 Marketed Cancer Cytokines Threapy

11. Cancer Cell Therapy Clinical Trial Insight by Phase & Country (Page 1844)
11.1 Clinical Pipeline Overview
11.2 Clinical Pipeline Insight: Research till Preregistration
11.3 Marketed Cancer Cell Therapy

12. Competitive Landscape: Business Overview & Product Pipeline (Page 1977)
12.1 Advaxis
12.2 Celldex Therapeutics
12.3 Dendreon Corporation
12.4 Galena Biopharma
12.5 ImmunoCellular Therapeutics
12.6 ImmunoGen
12.7 Inovio Pharmaceuticals
12.8 Merck
12.9 NeoStem Oncology
12.10 NewLink Genetics
12.11 Northwest Biotherapeutics
12.12 Novartis
12.13 Peregrine Pharmaceuticals
12.14 Roche
12.15 Seattle Genetics

Figure 1-1: Introduction to Cancer Therapies
Figure 1-2: Key Events in the History of Cancer Immunotherapy
Figure 2-1: Mechanism of Cancer Immunotherapy
Figure 3-1: Type of Cancer Immunotherapy

Figure 5-1: Cancer Immunotherapy Market Category
Figure 5-2: Cancer Immunotherapy Market (US$ Billion), 2014-2020
Figure 5-3: Cancer Immunotherapy Market by Region (%), 2014 & 2020
Figure 5-4: Regulatory Milestones for Cancer Immunotherapy

Figure 7-1: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2014
Figure 7-2: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2014

Figure 8-1: Cancer Vaccine Clinical Pipeline by Phase (%), 2014
Figure 8-2: Cancer Vaccine Clinical Pipeline by Phase (Number), 2014

Figure 9-1: Oncolytic Viruses Clinical Pipeline by Phase (%), 2014
Figure 9-2: Oncolytic Viruses Clinical Pipeline by Phase (Number), 2014

Figure 10-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
Figure 10-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014

Figure 11-1: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 11-2: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014

Figure 12-1: Advaxis Clinical Pipeline
Figure 12-2: Celldex Therapeutics Clinical Pipeline
Figure 12-3: Galena Biopharma Clinical Pipeline
Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 12-5: ImmunoGen Clinical Pipeline
Figure 12-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 12-7: NewLink Genetics Corporation Clinical Pipeline
Figure 12-8: Northwest Biotherapeutics Clinical Pipeline
Figure 12-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 12-10: Seattle Genetics Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.